Emory University

Children's Healthcare of Atlanta, Inc.

Georgia Tech Research Corporation

The Uab Research Foundation

Wake Forest University

H Trent Spencer

Anthony Atala

Christopher B Doering

Harrison C Brown

Eric Gaucher

Philip M Zakas

Max Dale Cooper

Brantley R Herrin

Lawrence S Lamb

G Yancey Gillespie

Anindya Dasgupta

Christopher D Porada

Maria Graca N D Almeida-Porada

The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.

Genetically engineered drug resistant T cells and methods of using the same

This disclosure relates to recombinant or chimeric FVIII proteins, variants, and vectors encoding the proteins containing one or more ancestral mutations. In certain embodiments, one or more protein domains comprise amino acid sequences that are derived from ancestrally reconstructed amino acid sequences. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising the proteins or vectors and related methods of inducing blood clotting.

Factor VIII proteins having ancestral sequences, expression vectors, and uses related thereto

Described are recombinant nucleic acid molecules for increased expression of Cas9 in human liver. In some embodiments, the recombinant nucleic acid molecules are provided in compositions and methods for gene editing, specifically using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).

Cas9 nucleic acid molecules and their use

This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.

Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer

Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.

Recombinant promoters and vectors for protein expression in liver and use thereof

CAS9 nucleic acid molecules and their use

Growing community of inventors

Marietta, GA, United States of America

H Trent Spencer